Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00295503 · OUTCOME

Response Rate

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma · Source last updated 2020-10-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
from time of enrollment to time of best response or death from any cause, whichever came first up to 100 months

What was measured

response was assessed by the RECIST criteria (version 1.0). Per those criteria, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Groups in this outcome

Cisplatin, Pemetrexed, Bevacizumab

cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cisplatin, Pemetrexed, Bevacizumab52

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cisplatin, Pemetrexed, Bevacizumab40Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        40
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    units
    Participants
description
response was assessed by the RECIST criteria (version 1.0). Per those criteria, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
groups
  1. description
    cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks
    id
    OG000
    title
    Cisplatin, Pemetrexed, Bevacizumab
param Type
NUMBER
reporting Status
POSTED
time Frame
from time of enrollment to time of best response or death from any cause, whichever came first up to 100 months
title
Response Rate
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice